ethylpyrrolidin-3-yl)amino]-benzenesulfonylamino}-1,1a,2,7b-tetrahydrocyclopropa-[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-{2-[((S)-1-ethylpyrrolidin-3-yl)amino]-benzenesulfonylamino}-1,1a,2,7b-tetrahydrocyclopropa-[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-(2-{[((R)-1-ethylpyrrolidine-3-carbonyl)amino]-methyl}-4-fluoro-benzenesulfonylamino)-1,1a,2,7b-tetrahydro-cyclopropa[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-[2-((Z)-3-diethylamino-2-methylprop-1-enyl)-4-fluorobenzene-sulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-{2-[2-((R)-1-ethylpyrrolidin-3-yl)ethylamino]-benzenesulfonylamino}-1,1a,2,7b-tetrahydrocyclopropa-[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-{2-[2-((S)-1-ethylpyrrolidin-3-yl)ethylamino]-benzenesulfonyl-amino}-1,1a,2,7b-tetrahydrocyclopropa-[c]chromene-4-carboxylic acid; (1aR,7bS)-5-[2-((S)-1-ethylpyrrolidin-3-yloxymethyl)-4-fluoro-benzenesulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa-[c]chromene-4-carboxylic acid; (1aR,7bS)-5-[2-((R)-1-ethylpyrrolidin-3-yloxymethyl)-4-fluoro-benzenesulfonylamino]-1,1a,2,7b-tetrahydro-cyclopropa-[c]chromene-4-carboxylic acid; (1aR,7bS) -5-[2-(1-ethylpiperidin-3-ylmethyl)-4-fluorobenzene-sulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1aR,7bS)-5-{2-[2-((R)-1-ethylpyrrolidin-2-yl)ethyl]-4-fluorobenzenesulfonyl-amino}-1,1a,2,7b-tetrahydrocyclopropa-[c]chromene-4-carboxylic acid; and pharmaceutically acceptable salts, stereoisomers, esters and prodrugs thereof.

33. A pharmaceutically acceptable composition comprising a compound of any one of claims 1-32 and a pharmaceutically acceptable excipient.

34. ~~A method of treating and/or controlling obesity, comprising administering to a patient in need thereof an effective amount~~ Use of a compound of any one of claims 1-32 in the manufacture of a medicament for treating and/or controlling obesity in a patient in need thereof.

35. ~~A method of inducing weight loss in a patient in need thereof, comprising administering to said patient an effective amount~~ Use of a compound of any one of claims 1-32 in the manufacture of a medicament for inducing weight loss in a patient in need thereof.

36. The ~~method~~ use of claim 34 or 35, wherein the patient is a human.

37. The ~~method~~ use of claim 34 or 35, wherein the patient is a cat or dog.

38. The ~~method~~ use of any one of claims 34-36, wherein the patient has a body mass index greater than or equal to about 30 kg/m^2 before the administration.

39. The ~~method~~ use of any one of claims 34-38, wherein the compound is to be administered orally.

40. The composition of claim 33, wherein the composition is formulated as a unit dose.

41. The composition of claim 33, wherein the composition is formulated for oral administration.

42. The composition of claim 33, wherein the composition is formulated for intravenous or subcutaneous administration.

43. The ~~method~~ use of claim 34 or 35, ~~comprising administering~~ wherein said medicament ~~compound~~ is to be administered in an amount sufficient to establish inhibition of intracellular MetAP2 effective to increase thioredoxin production in the patient and to induce multi organ stimulation of anti-obesity processes in the subject.

44. The ~~method~~ use of claim 43, ~~comprising administering~~ wherein said ~~compound~~ medicament is to be administered in an amount insufficient to reduce angiogenesis in the patient.